Real-World Dosing Patterns and Outcomes Among Patients With Chronic Lymphocytic Leukemia With or Without Dose Adjustment of First-Line Ibrutinib

被引：0
|
作者：
Rogers, Kerry [1 ]
Lu, Xiaoxiao [2 ]
Emond, Bruno [3 ]
Ding, Zhijie [2 ]
Lefebvre, Patrick [3 ]
Lafeuille, Marie-Helene [3 ]
Mavani, Heena [2 ]
Qureshi, Zaina [2 ]
Ghosh, Nilanjan [4 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] Janssen Sci Affairs, Horsham, PA USA
[3] Anal Grp Inc, Montreal, PQ, Canada
[4] Levine Canc Inst, Charlotte, NC USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CLL; dose adjustment; real-world dosing; ibrutinib; chronic lymphocytic leukemia; outcomes;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-586
引用
收藏
页码：S330 / S330
页数：1
相关论文
共 50 条
  • [31] Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: results of a single-center retrospective analysis
    Nuttall, Elisabeth
    Tung, Joanna
    Trounce, Ellie
    Johnston, Rosalynd
    Chevassut, Timothy
    JOURNAL OF BLOOD MEDICINE, 2019, 10 : 199 - 208
  • [32] Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia
    Patel, Kishan K.
    Isufi, Iris
    Kothari, Shalin
    Davidoff, Amy J.
    Gross, Cary P.
    Huntington, Scott F.
    BLOOD, 2020, 136 (17) : 1946 - 1955
  • [33] Real-world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis
    Seymour, Erlene K.
    Ruterbusch, Julie J.
    Beebe-Dimmer, Jennifer L.
    Schiffer, Charles A.
    CANCER, 2019, 125 (01) : 135 - 143
  • [34] Patient Characteristics and Time to Next Treatment With Ibrutinib and Anti-CD20 Monotherapy as First-Line Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Lu, Xiaoxiao
    He, Jinghua
    Ran, Tao
    Wu, Linda
    Panjabi, Sumeet
    Vose, Julie M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S273 - S273
  • [35] Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax plus Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors
    Ravelo, Arliene
    Patel, Achal
    To, Tu My
    Li, Sophia S.
    Huntington, Scott
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S345 - S345
  • [36] Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study
    Kabadi, Shaum M.
    Near, Aimee
    Wada, Keiko
    Burudpakdee, Chakkarin
    ADVANCES IN THERAPY, 2020, 37 (07) : 3129 - 3148
  • [37] Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia
    Salles, Gilles
    Bachy, Emmanuel
    Smolej, Lukas
    Simkovic, Martin
    Baseggio, Lucile
    Panovska, Anna
    Besson, Herve
    Healy, Nollaig
    Garside, Jamie
    Iraqi, Wafae
    Diels, Joris
    Pick-Lauer, Corinna
    Spacek, Martin
    Urbanova, Renata
    Lysak, Daniel
    Hermans, Ruben
    Lundbom, Jessica
    Callet-Bauchu, Evelyne
    Doubek, Michael
    ANNALS OF HEMATOLOGY, 2019, 98 (12) : 2749 - 2760
  • [38] Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada
    Huang, Steven J.
    Gerrie, Alina S.
    Young, Sean
    Tucker, Tracy
    Bruyere, Helene
    Hrynchak, Monica
    Galbraith, Paul
    Al Tourah, Abdulwahab J.
    Dueck, Gregory
    Noble, Michael C.
    Ramadan, Khaled M.
    Tsang, Peter
    Hardy, Edward
    Sehn, Laurie
    Toze, Cynthia L.
    LEUKEMIA RESEARCH, 2020, 91
  • [39] A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States
    Mato, Anthony
    Tang, Boxiong
    Azmi, Soraya
    Yang, Keri
    Han, Yi
    Zhang, Xiaowei
    Roeker, Lindsey
    Wallis, Nicola
    Stern, Jennifer C.
    Hedrick, Eric
    Huang, Jane
    Sharman, Jeff P.
    EJHAEM, 2023, 4 (01): : 135 - 144
  • [40] Venetoclax Plus Ibrutinib As First-line Treatment in Patients With Chronic Lymphocytic Leukemia: Meta-Analysis of Randomised Controlled Trials
    Tanriverdi, Lokman Hekim
    Sarici, Ahmet
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S349 - S349
12345